Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
Technology appraisal guidance
Reference number: TA1116
Published:
There will be an additional committee meeting held on the 23 October 2025. Due to the confidential nature of data being discussed, the meeting will be held in private.